Subscribe To
arbutus: 2 key catalysts to look forward to after easl data release
Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being adv...
June 29, 2022, 3:36 pm
This analyst says arbutus' easl presentations outline path for a functional cure for chronic hepatitis b
JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on arbu...
June 28, 2022, 3:54 pm
arbutus to present seven scientific posters at easl international liver congress™ 2022
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ET...
June 8, 2022, 2:05 am
arbutus biopharma corp (abus) ceo william collier on q1 2022 results - earnings call transcript
arbutus Biopharma Corp, Inc. (NASDAQ:ABUS ) Q1 2022 Earnings Conference Call May 5, 2022 8:45 AM ET Com...
May 5, 2022, 2:05 pm
arbutus biopharma (abus) reports q1 loss, tops revenue estimates
arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the qu...
May 5, 2022, 10:33 am
arbutus biopharma; long-term hold with advancements into several areas of interest
arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for He...
March 7, 2022, 4:33 pm
arbutus biopharma corporation (abus) ceo william collier on q4 2021 results - earnings call transcript
arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript...
March 3, 2022, 2:31 pm
arbutus biopharma corporation (abus) ceo william collier on q4 2021 results - earnings call transcript
arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript...
March 3, 2022, 2:31 pm
arbutus biopharma corporation (abus) ceo william collier on q4 2021 results - earnings call transcript
arbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call Transcript...
March 3, 2022, 2:31 pm
arbutus biopharma (abus) reports q4 loss, misses revenue estimates
arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quart...
March 3, 2022, 12:20 pm
arbutus biopharma (abus) reports q4 loss, misses revenue estimates
arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quart...
March 3, 2022, 12:20 pm
arbutus biopharma (abus) reports q4 loss, misses revenue estimates
arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quart...
March 3, 2022, 12:20 pm
arbutus, genevant sue moderna, citing patent infringement
Shares of arbutus Biopharma Corp. ABUS, +7.21% gained 11.0% in premarket trading on Monday after the co...
February 28, 2022, 9:24 am
arbutus, genevant sue moderna, citing patent infringement
Shares of arbutus Biopharma Corp. ABUS, +7.21% gained 11.0% in premarket trading on Monday after the co...
February 28, 2022, 9:24 am
arbutus, genevant sue moderna, citing patent infringement
Shares of arbutus Biopharma Corp. ABUS, +7.21% gained 11.0% in premarket trading on Monday after the co...
February 28, 2022, 9:24 am
arbutus files patent infringement lawsuit against moderna
arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for in...
February 28, 2022, 6:37 am
arbutus files patent infringement lawsuit against moderna
arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for in...
February 28, 2022, 6:37 am
arbutus files patent infringement lawsuit against moderna
arbutus Biopharma Corp said on Monday it had filed a lawsuit against Moderna Inc seeking damages for in...
February 28, 2022, 6:37 am
What's the outlook for arbutus biopharma?
The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing....
February 5, 2022, 8:55 am
What's the outlook for arbutus biopharma?
The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing....
February 5, 2022, 8:55 am